ElectroCore Earnings Call: Growth Surges, Losses Deepen

Electrocore ((ECOR)) has held its Q4 earnings call. Read on for the main highlights of the call.

ElectroCore’s latest earnings call painted a picture of a company balancing rapid revenue growth with mounting cost pressures and liquidity concerns. Management highlighted record quarterly sales, strong expansion in both prescription and wellness channels, and strategic moves like the Quell acquisition and leadership changes, while acknowledging wider losses and the need for tighter expense control.

Record Revenue Beats Expectations

ElectroCore reported record Q4 2025 revenue of $9.2 million, up 31% year over year, capping a full-year net sales figure of $32.0 million, up 27% versus 2024. The company said these results exceeded analyst consensus on both revenue and earnings per share, underscoring strong top-line momentum despite ongoing losses.

Prescription Growth Led by VA Channel

Prescription revenue climbed 23% year over year to roughly $26 million, driven by adoption of gammaCore and Quell in the Veterans Affairs hospital system. About 13,400 VA patients have used gammaCore so far, representing only around 2% penetration of the eligible VA headache market and signaling a significant growth runway.

General Wellness and Truvaga Scale Rapidly

The general wellness channel posted Q4 revenue of $1.4 million, up 31% year over year, bringing full-year wellness sales to $5.5 million, a 97% jump from 2024. Truvaga accounted for $5.4 million of that, rising 93% year over year on the back of stronger direct-to-consumer demand, media exposure, and new retail placements such as at a major electronics retailer.

Quell Acquisition and OTC Expansion Plans

Following the May 2025 acquisition of Quell, the product contributed about $1.5 million in revenue for the year, adding another leg to the prescription portfolio. Management plans to launch an over-the-counter Quell Relief product in the first half of 2026, positioning it as an incremental growth driver alongside existing channels.

Marketing Efficiency and E-Commerce Metrics

Return on advertising spend improved to roughly $2.10 in the latest period, compared with $1.80 in Q3 2025, suggesting more efficient customer acquisition. E-commerce conversion rates held steady at about 12% to 15%, and stripping out a one-time $0.5 million Truvaga clinical trial order, management said Truvaga revenue grew around 40% sequentially.

Adjusted EBITDA Trends Show Modest Progress

Adjusted EBITDA net loss narrowed slightly to $8.7 million for full-year 2025 from $9.0 million in 2024, reflecting incremental operational improvements and acquisition integration. While still firmly in negative territory, the modest improvement indicates early benefits from scale and cost discipline, even as spending remains elevated.

Leadership Transition and Commercial Build-Out

The CEO announced plans to retire effective April 1, 2026, with Joshua Lev slated to serve as interim president and chief financial officer during the transition. ElectroCore also hired Michael Fox as chief operating officer, bringing deep experience in federal and VA commercialization to accelerate growth in those priority channels.

GAAP Net Loss Widens on Higher Costs

Despite revenue gains, the GAAP net loss widened to $14.0 million, or $1.65 per share, in 2025 compared with a loss of $11.9 million, or $1.59 per share, a year earlier. Management attributed the deeper loss largely to higher operating expenses and other costs, including items linked to transactions and integration.

Operating and SG&A Expenses Climb Sharply

Total operating expenses rose to about $40.9 million in 2025 from $33.6 million in 2024, underscoring the investment-heavy growth strategy. Selling, general and administrative costs increased to $38.2 million, with sales and marketing up $4.3 million and general and administrative up $2.7 million due to legal fees, implementation spending, and deal-related expenses.

Nonrecurring Items and Interest Weigh on Results

Other expense reached $0.8 million for 2025, an increase of $1.0 million year over year as nonrecurring items accumulated. These included a $0.5 million change in an estimated liability and rising interest expense tied to term debt financing, adding incremental pressure to the bottom line.

Liquidity Pressure from Cash Decline

Cash and marketable securities stood at roughly $11.6 million at year-end 2025, down from $12.2 million previously, leaving investors focused on the company’s funding runway. With continued operating losses and elevated spending, management acknowledged that liquidity remains a key watch point as growth investments continue.

Early-Stage VA Penetration Despite Momentum

Management stressed that penetration in the VA headache market is still at an early stage, with gammaCore reaching only about 2% of the addressable patient population so far. This low base suggests substantial upside potential if the company can broaden facility coverage and drive higher utilization across the VA system.

Truvaga Trends Clouded by One-Time Order

Truvaga revenue was flat sequentially in Q4 when including a one-off $0.5 million clinical trial order booked in a prior period, complicating trend analysis. Executives argued that excluding this one-time item, Truvaga would show roughly 40% quarter-on-quarter growth, implying underlying demand is stronger than the headline figures suggest.

Guidance and 2026 Outlook

For 2026, management described potential full-year revenue growth of around 30% but stopped short of formal detailed guidance due to the ongoing leadership transition. They expect most revenue to continue coming from U.S. federal channels, plan a soft launch of Quell OTC in the first half, and emphasized that any sales from that product would be incremental to their rough growth outlook while they work toward profitability.

ElectroCore’s call underscored a company in the midst of rapid commercial expansion, with record revenue, fast-growing wellness brands, and underpenetrated VA opportunities offering attractive upside. At the same time, widening losses, rising expenses, and modest cash reserves keep the spotlight on execution and capital discipline, leaving investors weighing strong growth prospects against near-term financial risks.